BACKGROUND: While several studies have reported a link between the presence of gout and adverse cardiovascular (CV) events in the general population, none has addressed the question of whether the mortality risk of patients with gout is influenced by disease severity. METHODS: We applied survival analysis methodology to prospectively collected data on clinical and radiographic measures of disease severity and mortality in a specialty clinic based cohort of 706 patients with gout (1992-2008). Standardised mortality ratios (SMR) were calculated to assess the magnitude of excess mortality among patients with gout compared with the underlying general population. RESULTS: Mean follow-up was 47 months. Tophaceous deposition was present in 30.5% of patients; >4 joints were involved in 34.6% of cases. Mean annual flare rate was 3.4. Arterial hypertension (41.2%), hyperlipidaemia (42.2%), diabetes mellitus (20.1%), renal function impairment (26.6%) and a previous CV event (25.3%) were recorded. 64 (9.1%) patients died, death being attributed to vascular causes in 38 (59%) patients. SMR for gout patients was 2.37 (95% CI 1.82 to 3.03), 1.57 (1.18 to 2.05) and 4.50 (2.06 to 8.54) overall, and in men and women, respectively. The presence of tophi and the highest baseline serum urate (SU) levels were independently associated with a higher risk of mortality, in addition to age, loop diuretic use and a history of a previous vascular event. In the multivariable survival regression models, with time varying covariates, the presence of tophi remained a significant mortality risk after adjustment for baseline SU levels (1.98; 1.24 to 3.20). CONCLUSIONS: High baseline SU level and the presence of subcutaneous tophi were both associated with an increased risk of mortality in patients with gout, in most cases attributed to a CV cause. This suggests a plausible pathophysiological link between greater total body urate load and CV disease.
BACKGROUND: While several studies have reported a link between the presence of gout and adverse cardiovascular (CV) events in the general population, none has addressed the question of whether the mortality risk of patients with gout is influenced by disease severity. METHODS: We applied survival analysis methodology to prospectively collected data on clinical and radiographic measures of disease severity and mortality in a specialty clinic based cohort of 706 patients with gout (1992-2008). Standardised mortality ratios (SMR) were calculated to assess the magnitude of excess mortality among patients with gout compared with the underlying general population. RESULTS: Mean follow-up was 47 months. Tophaceous deposition was present in 30.5% of patients; >4 joints were involved in 34.6% of cases. Mean annual flare rate was 3.4. Arterial hypertension (41.2%), hyperlipidaemia (42.2%), diabetes mellitus (20.1%), renal function impairment (26.6%) and a previous CV event (25.3%) were recorded. 64 (9.1%) patients died, death being attributed to vascular causes in 38 (59%) patients. SMR for goutpatients was 2.37 (95% CI 1.82 to 3.03), 1.57 (1.18 to 2.05) and 4.50 (2.06 to 8.54) overall, and in men and women, respectively. The presence of tophi and the highest baseline serum urate (SU) levels were independently associated with a higher risk of mortality, in addition to age, loop diuretic use and a history of a previous vascular event. In the multivariable survival regression models, with time varying covariates, the presence of tophi remained a significant mortality risk after adjustment for baseline SU levels (1.98; 1.24 to 3.20). CONCLUSIONS: High baseline SU level and the presence of subcutaneous tophi were both associated with an increased risk of mortality in patients with gout, in most cases attributed to a CV cause. This suggests a plausible pathophysiological link between greater total body urate load and CV disease.
Entities:
Keywords:
Cardiovascular Disease; Gout; Outcomes research
Authors: A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich Journal: Rheumatol Int Date: 2013-09-12 Impact factor: 2.631
Authors: Tomas Cazenave; Victoria Martire; Anthony M Reginato; Marwin Gutierrez; Christian Alfredo Waimann; Carlos Pineda; Javier Eduardo Rosa; Santiago Ruta; Oscar Sedano-Santiago; Ana Maria Bertoli; Marcelo Audisio; Cristina Hernandez-Diaz; Lucio Ventura-Rios; Maritza Quintero; Eugenio De Miguel; Ana Laura Alvarez-Del-Castillo-Araujo; Andy Abril; Eliana Natalí Ayala-Ledesma; Edith Alarcon-Isidro; Maria Lida Santiago; Mariana Alejandra Pera; Cecilia Urquiola; Gustavo Rodriguez Gil; Lina Maria Saldarriaga Rivera; Cesar Cefferino; Mariana Benegas; Mario Enrique Diaz Cortes; Maximiliano Bravo; Diana Peiteado; Natalia Anahi Estrella; Roser Areny Micas; Jorge Saavedra Muñoz; Rodolfo Del Carmen Arape Toyo; Maria Soledad Gálvez Elkin; Walter Javier Spindler; Clarisa Sandobal; Josefina Marin; Manuella Lima Gomes Ochtrop; Ricardo Pavao Ayala; Erika Roxana Catay; Guillermo Enrique Py; Gabriel Hector Aguilar; Yvonne Yona Rengel Colina; Carla Antonela Airoldi; Claudia Selene Mora-Trujillo; Maria Paula Kohan; Lorena Evelin Urioste Eguez; Concepción Castillo-Gallego; Jose Francisco Diaz-Coto; Patricio Tate; Carla Magali Saucedo; Oscar Vega-Hinojosa; Cristian Jonatan Troitiño; Maria Florencia Marengo; Priscila Maria Marcaida; Irene Monjo Henry; Roberto Muñoz-Louis; Carla Solano; Felix Reinaldo Fernandez Castillo; Cesar Enrique Graf; Mara Guinsburg; Maria Julia Santa Cruz; David Alejandro Navarta Ortiz; Magaly Alva Linares; Marcos Gabriel Rosemffet Journal: Rheumatol Int Date: 2018-12-11 Impact factor: 2.631
Authors: Iris J M Disveld; Sahel Zoakman; Tim L Th A Jansen; Gerard A Rongen; Laura B E Kienhorst; Hein J E M Janssens; Jaap Fransen; Matthijs Janssen Journal: Clin Rheumatol Date: 2019-03-30 Impact factor: 2.980
Authors: Dodji V Modjinou; Svetlana Krasnokutsky; Soterios Gyftopoulos; Virginia C Pike; Elaine Karis; Robert T Keenan; Kristen Lee; Daria B Crittenden; Jonathan Samuels; Michael H Pillinger Journal: Clin Rheumatol Date: 2017-06-16 Impact factor: 2.980